Ovarian, Uterine, and Vulvovaginal Cancers: Screening, Treatment Overview, and Prognosis

Deborah Gomez Kwolek; Stefanie Gerstberger; Sarah Tait; Jeanna M Qiu

doi:10.1016/j.mcna.2022.10.016

Ovarian, Uterine, and Vulvovaginal Cancers: Screening, Treatment Overview, and Prognosis

Med Clin North Am. 2023 Mar;107(2):329-355. doi: 10.1016/j.mcna.2022.10.016. Epub 2023 Jan 2.

Authors

Deborah Gomez Kwolek¹, Stefanie Gerstberger², Sarah Tait³, Jeanna M Qiu⁴

Affiliations

¹ Department of Medicine, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA; Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA. Electronic address: dkwolek@mgh.harvard.edu.
² Department of Medicine, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA; Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
³ Department of Medicine, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.
⁴ Department of Medicine, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA; Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA.

PMID: 36759101
DOI: 10.1016/j.mcna.2022.10.016

Abstract

Ovarian, uterine, and vulvovaginal cancers affect approximately 96,000 women per year in the United States, resulting in approximately 29,000 deaths annually. Routine screening protocols do not detect these malignancies; thus, the recognition of risk factors and evaluation of worrisome symptoms are essential for early detection and improved prognoses. Treatment is managed by gynecologic oncologists, and often involves a combination of surgery, chemotherapy, and possible radiation treatments. Survivor care is managed by the primary-care clinician: expert attention to the mental, physical, and sexual health of each patient will ensure the best outcomes and quality of life.

Keywords: Ovarian cancer; Uterine cancer; Vaginal cancer; Vulvar cancer.

Publication types

Review

MeSH terms

Early Detection of Cancer
Female
Humans
Neoplasms*
Prognosis
Quality of Life*
Risk Factors
United States

Grants and funding

T32 GM007753/GM/NIGMS NIH HHS/United States